MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$244.83M

FY 2025 · Annual

Net Income

-$227.32M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.97K0002.62M
Gross Profit(4.97K)000(2.62M)
Gross Margin—————
Research & Development35.52M42.05M31.8M112.77M202.86M
Selling, General & Admin18.05M23.01M22.32M30.32M41.97M
Operating Expenses53.57M65.06M54.12M143.09M242.22M
Depreciation & Amortization4.97K164.78K370.32K1.38M2.62M
EBITDA(53.63M)(64.3M)(43.61M)(119.58M)(219.85M)
EBITDA Margin—————
Operating Income(53.58M)(65.06M)(54.12M)(143.09M)(244.83M)
Operating Margin—————
Interest Income00000
Interest Expense00007.25M
Other Income / Expenses(61.85K)591.73K10.14M22.13M15.12M
Income Before Tax(53.64M)(64.47M)(43.98M)(120.96M)(229.71M)
Pre-Tax Margin—————
Income Tax Expense4.76K36.37K94.39K282.2K611K
Net Income(53.64M)(49.97M)(36.01M)(118.94M)(227.32M)
Net Margin—————
EPS (Basic)(1.45)(2.20)(0.73)(1.89)(3.53)
EPS (Diluted)(1.45)(2.20)(0.73)(1.89)(3.53)
Weighted Avg Shares36.93M29.36M49.12M62.87M64.46M
Weighted Avg Shares (Diluted)36.93M29.36M49.12M62.87M64.46M

MLTX Earnings Waterfall · TTM

NASDAQ:MLTX · Revenue to Net Income

Key Ratios

EPS$-3.88
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.8
P/S Ratio0.0

Analysis

$0 of revenue converted into -$257.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.88, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportSep 30, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13GSC 13G filingAug 14, 2026

How much revenue does MLTX generate?

MoonLake Immunotherapeutics (MLTX) reported $0.00 of revenue in fiscal 2025.

Is MLTX profitable?

MoonLake Immunotherapeutics (MLTX) reported -$227.32M of net income.